Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review

A Huang, I Castrejon - Rheumatology international, 2016 - Springer
Patient-reported outcomes (PROs) are being increasingly recognized as important
measures by rheumatologists. The objective of this review was to evaluate the frequency of …

Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development

L Iorio, R Padoan, M Bond, C Dejaco - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disorder
characterized by pain and stiffness in the shoulder and pelvic girdles, constitutional …

Risk factors for relapse and/or prolonged glucocorticoid therapy in polymyalgia rheumatica: multicenter study in 185 patients

JP Vinicki, O Gut, M del Rosario Maliandi… - JCR: Journal of …, 2024 - journals.lww.com
Background In polymyalgia rheumatica (PMR) relapses and long-term GC dependency are
common. We assessed risk factors for higher relapse rate and/or prolonged glucocorticoid …

POS0269 RESULTS OF ONE YEAR OBSERVATIONAL EXTENSION OF THE BRIDGE-PMR STUDY, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED …

T Bolhuis, D Marsman, A Den Broeder, N Den Broeder… - 2022 - ard.bmj.com
Background Glucocorticoids (GC) are the cornerstone of treatment in Polymyalgia
rheumatica (PMR)[1]. However, they are associated with considerable toxicity and inefficacy …

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry

SE Sattui, F Xie, Z Wan, C Clinton… - Arthritis Care & …, 2024 - Wiley Online Library
Objective This study describes the demographics, comorbidities, and treatment patterns in a
national cohort of patients with polymyalgia rheumatica (PMR) who received care from …

Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm?

C Ricordi, N Pipitone, C Marvisi… - Expert Review of …, 2023 - Taylor & Francis
Introduction Polymyalgia rheumatica is a common inflammatory rheumatic disease in
subjects aged 50 years or older and classically presents with shoulder and/or pelvic girdle …

Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study

S Muller, SL Hider, B Singh Sokhal… - … Advances in Practice, 2022 - academic.oup.com
Objectives PMR is a common inflammatory condition in older adults, characterized by
bilateral hip and shoulder pain and stiffness. Reducing oral glucocorticoids, classically used …

Outcomes of polymyalgia rheumatica in real-world practice: a longitudinal cohort study

M Rahimi, K Esalatmanesh, S Daneshvar… - Romanian Journal of …, 2024 - sciendo.com
Background: Polymyalgia rheumatica (PMR) is an inflammatory condition closely linked with
giant cell arteritis, which is a large vessel vasculitis. To provide real-world evidence on PMR …

[PDF][PDF] Polymyalgia rheumatica-an up-to-date review on diagnosis and management

P Harkins, L McCann, R Harrington, S Cowley, D Kane… - 2024 - f.oaes.cc
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in
those over the age of 50 years. Previously it was considered to be a benign clinical …

[HTML][HTML] PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind …

DE Marsman, TE Bolhuis, N den Broeder… - Trials, 2022 - Springer
Background Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting
people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle …